Merck's M&A chief expects 'a lot more deal flow' as Keytruda patent cliff nears

Merck's business development chief Sunil Patel says the drugmaker wants more deals as it diversifies beyond Keytruda ahead of its 2028 patent cliff.

Raccontata daendpoints.news